[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Monday Afternoon",
    "summary": "Health care stocks rose Monday afternoon, with the NYSE Health Care Index and the Health Care Select",
    "url": "https://finnhub.io/api/news?id=51ad20275ada0ac22971eb16ab943bbf83f427e8ac76341d7356805cbdd2b16a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760377350,
      "headline": "Sector Update: Health Care Stocks Advance Monday Afternoon",
      "id": 137068576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Health care stocks rose Monday afternoon, with the NYSE Health Care Index and the Health Care Select",
      "url": "https://finnhub.io/api/news?id=51ad20275ada0ac22971eb16ab943bbf83f427e8ac76341d7356805cbdd2b16a"
    }
  },
  {
    "ts": null,
    "headline": "AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve",
    "summary": "AstraZeneca secures a three-year tariff break after striking a landmark U.S. deal to cut drug prices and expand its domestic manufacturing.",
    "url": "https://finnhub.io/api/news?id=1480f66d706d835623c6a351a69c2d21b03fe4681b3b19910e0dc7f1cd409960",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760377200,
      "headline": "AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve",
      "id": 137070417,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AstraZeneca secures a three-year tariff break after striking a landmark U.S. deal to cut drug prices and expand its domestic manufacturing.",
      "url": "https://finnhub.io/api/news?id=1480f66d706d835623c6a351a69c2d21b03fe4681b3b19910e0dc7f1cd409960"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease",
    "summary": "AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD).",
    "url": "https://finnhub.io/api/news?id=de5d37fbf2a6fc3dcf902c50a7468574252669bec053ffe0338b44b2a6a30655",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760367420,
      "headline": "U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease",
      "id": 137068577,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD).",
      "url": "https://finnhub.io/api/news?id=de5d37fbf2a6fc3dcf902c50a7468574252669bec053ffe0338b44b2a6a30655"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Income: Lanny's August 2025 Summary",
    "summary": "We had more stocks increase last month, but the increases this month provided much more growth to the forward passive income stream. Read more here.",
    "url": "https://finnhub.io/api/news?id=d8a1ef1b61cd64fdc95901ee2893c34928b7fce6312763bba68ab0a8e565e57c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760364000,
      "headline": "Dividend Income: Lanny's August 2025 Summary",
      "id": 137068252,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2205959448/image_2205959448.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "We had more stocks increase last month, but the increases this month provided much more growth to the forward passive income stream. Read more here.",
      "url": "https://finnhub.io/api/news?id=d8a1ef1b61cd64fdc95901ee2893c34928b7fce6312763bba68ab0a8e565e57c"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Stocks to Double Up on Right Now",
    "summary": "These two companies can help you sleep easy at night.",
    "url": "https://finnhub.io/api/news?id=284e2766b6fb864333af5e85a30538f723f88bcdba396d47b8b83932ec2013e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760363580,
      "headline": "2 Dividend Stocks to Double Up on Right Now",
      "id": 137068578,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "These two companies can help you sleep easy at night.",
      "url": "https://finnhub.io/api/news?id=284e2766b6fb864333af5e85a30538f723f88bcdba396d47b8b83932ec2013e8"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Gets Expanded FDA Approval for Rinvoq Drug",
    "summary": "AbbVie Gets Expanded FDA Approval for Rinvoq Drug",
    "url": "https://finnhub.io/api/news?id=dee64b27bf8982a6fe404edb502e609c7ab621e2eb418efc8bdb5ca123726b4e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760355060,
      "headline": "AbbVie Gets Expanded FDA Approval for Rinvoq Drug",
      "id": 137077716,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Gets Expanded FDA Approval for Rinvoq Drug",
      "url": "https://finnhub.io/api/news?id=dee64b27bf8982a6fe404edb502e609c7ab621e2eb418efc8bdb5ca123726b4e"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors",
    "summary": "AbbVie (NYSE: ABBV) today announced it will unveil new data from its robust antibody-drug conjugate (ADC) platform at the 2025 European Society for Medical Oncology (ESMO) Congress, taking place October 17-21, in Berlin, Germany. Data from investigational and approved ADCs across AbbVie's portfolio such as telisotuzumab adizutecan (Temab-A),1-3 ABBV-706,4,5 and Emrelis™ (telisotuzumab vedotin),6 in patients with difficult-to-treat tumor types where there is urgent need for additional treatment o",
    "url": "https://finnhub.io/api/news?id=933541459c2284eefc2983692969f54312c15d10f1cdb4faa10a39c8998a10cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760354100,
      "headline": "AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors",
      "id": 137066315,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced it will unveil new data from its robust antibody-drug conjugate (ADC) platform at the 2025 European Society for Medical Oncology (ESMO) Congress, taking place October 17-21, in Berlin, Germany. Data from investigational and approved ADCs across AbbVie's portfolio such as telisotuzumab adizutecan (Temab-A),1-3 ABBV-706,4,5 and Emrelis™ (telisotuzumab vedotin),6 in patients with difficult-to-treat tumor types where there is urgent need for additional treatment o",
      "url": "https://finnhub.io/api/news?id=933541459c2284eefc2983692969f54312c15d10f1cdb4faa10a39c8998a10cd"
    }
  },
  {
    "ts": null,
    "headline": "Hugel Inc. appoints Carrie Strom as Chief Executive Officer",
    "summary": "Hugel Inc., a leading global medical aesthetics company publicly traded in South Korea, announced today that industry veteran Carrie Strom has been appointed President and Global Chief Executive Officer, and is expected to be appointed to a member of the Board of Directors following approval at a forthcoming shareholders' meeting. Ms. Strom will start the newly established global CEO role on October 13, 2025. The Hugel Inc. executive leadership team will report directly to Ms. Strom, including t",
    "url": "https://finnhub.io/api/news?id=a15389b7e4182ece8bf134fa12a25fd3622edd8b2b3fbc1ad775236683e9d573",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760338800,
      "headline": "Hugel Inc. appoints Carrie Strom as Chief Executive Officer",
      "id": 137066316,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Hugel Inc., a leading global medical aesthetics company publicly traded in South Korea, announced today that industry veteran Carrie Strom has been appointed President and Global Chief Executive Officer, and is expected to be appointed to a member of the Board of Directors following approval at a forthcoming shareholders' meeting. Ms. Strom will start the newly established global CEO role on October 13, 2025. The Hugel Inc. executive leadership team will report directly to Ms. Strom, including t",
      "url": "https://finnhub.io/api/news?id=a15389b7e4182ece8bf134fa12a25fd3622edd8b2b3fbc1ad775236683e9d573"
    }
  }
]